title: Management of Benign Prostatic Hyperplasia in Older Adults.
abstract: Benign prostatic hyperplasia (BPH), also known as benign prostatic hypertrophy, is a nonmalignant adenomatous overgrowth of the periurethral prostate gland commonly seen in aging men. Historically, it has been assumed that the pathophysiology of lower urinary tract symptoms in men is the result of bladder outlet obstruction associated with prostate enlargement. Symptoms such as urinary hesitancy, incomplete bladder emptying, dribbling or prolonged urination, nocturia, urinary urgency, and/or urge incontinence are common. Understanding the differential diagnosis and ordering appropriate laboratory tests are essential in accurately identifying a BPH diagnosis. Management can be broken down into medical or pharmacological and surgical therapies. This article aims to provide an overview of BPH and its management in older adults.
authors.affiliation: Peach State Health Plan, Atlanta, Georgia, USA.
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Woodard
authors.forename: Kendra R
authors.initials: KR
authors.lastname: Manigault
authors.forename: Niesha N
authors.initials: NN
authors.lastname: McBurrows
authors.forename: Tiffany L
authors.initials: TL
authors.lastname: Wray
authors.forename: Laresa M
authors.initials: LM
authors.lastname: Woodard
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D000367:Age Factors; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D019060:Minimally Invasive Surgical Procedures; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D020728:Transurethral Resection of Prostate; D016896:Treatment Outcome; D064804:Urological Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D018727:Muscarinic Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D064804:Urological Agents